Atomoxetine Beyond ADHD: A Fact or Aritfact
American Journal of Psychiatry and Neuroscience
Volume 3, Issue 5, September 2015, Pages: 90-93
Received: Jul. 10, 2015; Accepted: Jul. 23, 2015; Published: Aug. 6, 2015
Views 3444      Downloads 82
Ahmed Naguy, Al-Manara Centre for CAP, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait
Ali Al-Tajali, General Adult Psychiatrist, Head of Neuromodulation Unit, KCMH, Shuwaikh, State of Kuwait
Article Tools
Follow on us
Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the literature abound portraying a multitude of indications with variable level of evidence oscillating from strong to only flimsy. Here, we shed light on these uses and testing extant evidence.
Atomoxetine-Pharmacology-Clinical Uses-Off Label Uses
To cite this article
Ahmed Naguy, Ali Al-Tajali, Atomoxetine Beyond ADHD: A Fact or Aritfact, American Journal of Psychiatry and Neuroscience. Vol. 3, No. 5, 2015, pp. 90-93. doi: 10.11648/j.ajpn.20150305.12
Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26
Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711
Ding YS, Naganawa M, Gallezot JD et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. Neuroimage. 2014;86:164-71
Ludolph AG, Udvardi PT, Schaz U, et al. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol. 2010;160(2):283-91
Kobayashi T, Washiyama K, Ikeda K. Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxitine. Neuropsychopharmacology. 2010;35(7):1560-9
Creighton CJ, Ramabadran K, Ciccone PE, et al. Synthesis and biological evaluation of the major metabolite of atomoxetine : elucidation of a partial kappa-opioid agonist effect. Bioorg Med Chem Lett. 2004;14(15):4083-5
Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915-24
Berigan TR. Atomoxetine used adjunctively with selective serotonin reuptake inhibitors to treat depression. Prim Care Companion J Clin Psychiatry. 2004;6(2):93-94
Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline : a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(4):582-7
Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448-55
Ravindran LN, Kim DS, Letamendi AM, et al. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol. 2009;29(6):561-4
McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder : a randomized placebo-controlled trial. J Clin Psychiatry. 2007;68(3):390-8
Ball MP, Warren KR, Feldman S, et al. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizphr Relat Psychoses. 2011;5(1):17-25
Friedman JI, Carpenter D, Lu J, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol. 2008;28(1):59-63
Kelly DL, Buchanan RW, Boggs DL, et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry. 2009;70(4):518-25
Naguy A, Al-Mutairi H. Add-on atomoxetine mitigated different symptom domains in a case of Early-onset schizophrenia. J Psychiatry. 2015;18:279
Poyurovsky M, Fuchs C, Pashinian A, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007;192(3):441-8
Jancovic J. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009;284(1-2):177-8
Marsh L, Biglan K, Gerstenhaber M, et al. Atomoxetine for the treatment of executive dysfunction in Parkinson’s Disease : a pilot open-label study. Mov Disord. 2009;24(2):277-82
Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29(5):484-7
Mohs RC, Shiovitz TM, Tariot PN, et al. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease : 6-month, randomized, double-blind, placebo-controlled, parallel trial study. Am J Geriatr Psychiatry. 2009;17(9):752-9
Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders : placebo-controlled cross-over pilot study. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-205
Sumner CR, Schuh KJ, Sutton VK, et al. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol. 2006;16(6):699-711
Shatkin JP. Atomoxetine for the treatment of pediatric nocturnal enuresis. J Child Adolesc Psychopharmacol. 2004;14(3):443-7
Clark N. Conventional Antipsychotic and clozapine-induced urinary incontinence. JCPNP. 2003;2(2).
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186